Literature DB >> 17337432

A comparative study of the effects of hypoglycemic agents on serum electrolytes in the diabetic patients.

Aisha Javaid1, Ruqaiya Hasan, Asma Zaib, Shama Mansoor.   

Abstract

30 patients comprised of 3 equal groups which were given 3 types of treatment. Group I given metformin HCl (1+1), maintained a sugar level of 129-340 mg/100 ml. Group II given glibenclamide(1+1), maintained a sugar level of 120-325 mg/100 ml. Group III given a combination of both drugs, maintained a sugar level 112 mg - 46 mg/100 ml. The most suitable of the 3 was the last treatment. Serum electrolytes were measured in all the three groups. Patients taking metformin HCl and glibenclamide showed non significant low sodium with high potassium values respectively. When used in combination, they maintained normal values. On the other hand, serum calcium levels were significantly high in patients taking metformin HCl only; when compared with glibenclamide. However, when both drugs were given to patients, serum calcium remained at normal levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17337432

Source DB:  PubMed          Journal:  Pak J Pharm Sci        ISSN: 1011-601X            Impact factor:   0.684


  4 in total

Review 1.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

2.  Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.

Authors:  Kasper S Madsen; Pernille Kähler; Lise Katrine Aronsen Kähler; Sten Madsbad; Filip Gnesin; Maria-Inti Metzendorf; Bernd Richter; Bianca Hemmingsen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-18

3.  Pattern of electrolyte imbalance in Type 2 diabetes patients: Experience from a tertiary care hospital.

Authors:  Rashid Naseem Khan; Farhana Saba; Syedhh Fatima Kausar; Muhammad Hassan Siddiqui
Journal:  Pak J Med Sci       Date:  2019       Impact factor: 1.088

4.  In Vitro and In Vivo Quality Evaluation of Glibenclamide Tablets Marketed in Addis Ababa, Ethiopia.

Authors:  Haile Kassahun; Kaleab Asres; Ayenew Ashenef
Journal:  J Pharm (Cairo)       Date:  2018-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.